Premium
Gingival Crevicular Fluid MMP‐8 and −13 and TIMP‐1 Levels in Patients With Rheumatoid Arthritis and Inflammatory Periodontal Disease
Author(s) -
Bıyıkoğlu Başak,
Buduneli Nurcan,
Kardeşler Levent,
Aksu Kenan,
Pitkala Marjut,
Sorsa Timo
Publication year - 2009
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2009.090130
Subject(s) - rheumatoid arthritis , matrix metalloproteinase , medicine , periodontal disease , arthritis , dentistry
Background: The purpose of this study was to compare gingival crevicular fluid (GCF) levels of matrix metalloproteinase (MMP)‐8 and −13 and tissue inhibitor of MMP (TIMP)‐1 in patients with rheumatoid arthritis (RA) and systemically healthy counterparts with inflammatory periodontal disease. Methods: Subjects (N = 74) were divided into five groups: 12 patients with RA and gingivitis; 13 patients with RA and periodontitis; 12 systemically healthy patients with gingivitis; 13 systemically healthy patients with periodontitis; and 24 periodontally and systemically healthy volunteers. Full‐mouth clinical periodontal measurements were performed at six sites/tooth. GCF samples obtained from two sites in single‐rooted teeth were analyzed by immunofluorometric assay and enzyme‐linked immunosorbent assay. Data were assessed statistically by parametric tests. Results: The total amounts of MMP‐8 were lower in the healthy control group than in RA‐gingivitis, RA‐periodontitis, and healthy‐periodontitis groups ( P <0.05). MMP‐13 levels were similar in all five study groups ( P >0.05). Patients with RA and gingivitis or periodontitis exhibited levels of MMP‐8 and −13 and TIMP‐1 that were similar to systemically healthy counterparts ( P >0.05). Conclusions: The coexistence of RA and periodontitis did not significantly affect the investigated parameters. GCF MMP‐8 levels increased with periodontal inflammation. Despite the long‐term usage of corticosteroids and non‐steroidal anti‐inflammatory drugs, similar GCF MMP‐8 and −13 levels in patients with RA and systemically healthy counterparts suggest that RA may create a tendency to overproduce these enzymes.